article thumbnail

Incyte plots Delaware expansion as it looks to re-wed commercial, medical teams in its home state

Fierce Pharma

. | Incyte revealed plans to purchase buildings at 1100 North King Street and 1100 North French street in downtown Wilmington, Delaware, where the company got its start back in 2002.

Medical 208
article thumbnail

First patient receives new engineered mRNA epigenetic

European Pharmaceutical Review

revealed the first patient to be dosed with OTX-2002, the first programmable mRNA therapeutic for c-Myc (MYC) oncogene overexpression, which targets cancer cells while sparing healthy cells. OTX-2002 is delivered via lipid nanoparticles (LNPs) and controls the expression of specific genes using epigenetics, a new era of medicine. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Leprosy potentially endemic in Central Florida

Pharmaceutical Technology

The proportion of cases found in migrants to Florida has decreased significantly since 2002 while cases in US residents has risen.

article thumbnail

Lung cancer deaths decline but.

World of DTC Marketing

The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019.

Medicine 271
article thumbnail

BDR Pharmaceuticals- Openings for Production/ QA/ QC/ CVC/ Packing/ Engineering- Apply Now

Pharma Pathway

BDR Pharmaceuticals- Openings for Production/ QA/ QC/ CVC/ Packing/ Engineering- Apply Now Job Description BDR Pharmaceuticals was Established in 2002 into API manufacturing, We have a consolidated position in the domestic and global market for the API Business.

article thumbnail

Key developments: mRNA vaccines and therapeutics

European Pharmaceutical Review

OTX-2002, the first mRNA therapy to target c-Myc (MYC) oncogene overexpression, could be the first programmable epigenetic medicine.” ” OTX-2002, the first mRNA therapy to target c-Myc (MYC) oncogene overexpression, could be the first programmable epigenetic medicine, with the potential to generate $1.6

article thumbnail

BDR Pharmaceuticals-Walk-In Drive for Production/ QA/ QC/ ADL/ Engineering On 25th Feb’ 2023

Pharma Pathway

BDR Pharmaceuticals-Walk-In Drive for Production/ QA/ QC/ ADL/ Engineering On 25th Feb’ 2023 Job Description BDR Pharmaceuticals was Established in 2002 into API manufacturing, We have a consolidated position in the domestic and global market for the API Business.